Consequently, the 2022 Consensus Report on the Management of Hyperglycemia in T2DM by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommends GLP-1 RAs as second-line therapy for the treatment of T2DM because of their organ protection benefits beyond improving glycemic control [4]. Here, GLP1R is linked to diabetes mellitus.